Stock page
Aurion Biotech Inc (AURN)
Aurion Biotech Inc is a clinical-stage biotechnology company committed to developing and commercializing disease-modifying, regenerative therapies. It is a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases. The company first-generation cell therapy product, HCEC-1 launched commercially under the marketed name Vyznova. Its next-generation product candidate, AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits, including manufacturing scalability and extended shelf life.
Quote snapshot
$0.00
Daily change: —
ExchangeNYSE
Updated2026-05-09T04:30:37.685883Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|